506710366 06/11/2021

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT6757184

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
WARSAW ORTHOPEDIC, INC.	09/25/2020

RECEIVING PARTY DATA

Name:	COMPANION SPINE, LLC
Street Address:	505 PARK AVENUE
Internal Address:	14TH FLOOR
City:	NEW YORK
State/Country:	NEW YORK
Postal Code:	10022

PROPERTY NUMBERS Total: 1

Property Type	Number
Patent Number:	8317832

CORRESPONDENCE DATA

Fax Number: (203)286-5137

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 2032865140

Email: jenn.welborn@farberllc.com

Correspondent Name: **FARBER LLC**

Address Line 1: 4 CORPORATE DRIVE

Address Line 2: **SUITE 287**


Address Line 4: SHELTON, CONNECTICUT 06484

ATTORNEY DOCKET NUMBER:	COM 1323 CON
NAME OF SUBMITTER:	TRAM ANH NGUYEN
SIGNATURE:	/Tram Anh Nguyen/
DATE SIGNED:	06/11/2021

Total Attachments: 8

source=2 - assignment (Warsaw to Companion)#page1.tif source=2 - assignment (Warsaw to Companion)#page2.tif source=2 - assignment (Warsaw to Companion)#page3.tif source=2 - assignment (Warsaw to Companion)#page4.tif

506710366



PATENT ASSIGNMENT

This Patent Assignment (this "<u>Assignment</u>") is dated as of September 25, 2020, and is made from **Medtronic, Inc.**, a Minnesota corporation ("<u>Assignor</u>") having an address of Operations Headquarters, 710 Medtronic Parkway, Minneapolis, Minnesota 55432-5604, and the Seller Affiliates to **Companion Spine, LLC**, a Delaware limited liability company ("<u>Assignee</u>") having an address of 505 Park Avenue, 14th Floor, New York, New York 10022.

WHEREAS, upon the terms and subject to the conditions of the Asset Purchase Agreement dated as of September 25, 2020 (as amended, modified or supplemented from time to time, the "Asset Purchase Agreement") between Medtronic, Inc., a Minnesota corporation ("Seller") and Companion Spine, LLC, a Delaware limited liability company ("Buyer"), and consistent with Schedule 2.1(a)(iv) of Exhibit A, Disclosure Letter to the Asset Purchase Agreement dated as of September 25, 2020 (as amended, modified or supplemented from time to time, the "Disclosure Letter"), delivered in connection with the Asset Purchase Agreement, Seller agreed to cause the Seller Affiliates (as defined in Schedule A of the Asset Purchase Agreement and Disclosure Letter) to sell, convey, assign and transfer to Buyer, and Buyer agreed to purchase, acquire and accept certain assets related to the Product Lines, including the Patents identified on Schedule 1 attached hereto (collectively, the "Assigned Patents).

NOW, THEREFORE, in consideration of the premises and the agreements contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

- 1. Capitalized terms used but not defined herein shall have the meanings given to such terms in the Asset Purchase Agreement.
- 2. Effective as of the date hereof, Assignor hereby sells, conveys, assigns and transfers to Assignee, and Assignee hereby purchases, acquires and accepts from Assignor, all the right, title and interest of Assignor in, to and under the Assigned Patents, together with all rights to: (i) claim priority in all countries in the Territory in accordance with the laws of such countries based thereon, (ii) collect royalties and proceeds in connection with any of the foregoing, (iii) apply for, prosecute, and seek patents in the Territory in respect of any of the inventions to the extent fully supported by the Assigned Patents, and (iv) sue for past, present or future infringement of said Assigned Patents together with all claims for damages for reason of past, present or future infringement of said Assigned Patents, and the right to sue for and collect the same for Assignee's own use and enjoyment, all to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor had this Assignment not been made.
- 3. From and after the date hereof, Assignee shall be responsible for and shall pay all costs relating to the registration, maintenance and prosecution of the Assigned Patents, including payment of any associated fees therefor, for the notarization, authentication, legalization or consularization of the signatures hereof, and for the recording of such assignment documents with the appropriate Governmental Entities.
- 4. Assignor hereby authorizes Assignee to record this Assignment with the applicable patent offices or other relevant Governmental Entity to record Assignee as the assignee

and owner of the Assigned Patents, including any reissuances, continuations, divisions, continuations-in part, revisions, extensions and reexaminations with respect thereto.

- 5. For a period of up to one year after the date hereof, and for no further consideration, each of the parties hereto shall, and shall cause its Affiliates to, execute, acknowledge and deliver such assignments, transfers, consents, assumptions and other documents and instruments and take such other commercially reasonable actions as may reasonably be requested to more effectively assign, convey or transfer to or vest in Assignee the Assigned Patents at Assignee's cost.
- 6. Neither the making nor the acceptance of this Assignment shall enlarge, restrict or otherwise modify any of the terms or conditions of the Asset Purchase Agreement or any of the Ancillary Agreements and nothing herein shall constitute a waiver or release by any party to the Asset Purchase Agreement or any of the Ancillary Agreements of any liabilities, duties or obligations imposed thereby. In the event of any conflict between the provisions of this Assignment, on the one hand, and the provisions of the Asset Purchase Agreement (including all Schedules and Exhibits thereto), on the other hand, the provisions of the Asset Purchase Agreement shall control.
- 7. This Assignment and the rights and obligations hereunder shall be binding upon and inure solely to the benefit of the parties hereto, their respective successors and permitted assigns.
- 8. This Assignment may be executed in one or more counterparts, each of which shall be deemed an original and all of which shall be deemed to constitute the same agreement. If any signature is delivered by facsimile transmission or by email in portable document format ("PDF"), such signature shall create a valid and binding obligation of the party executing (or on whose behalf the signature is executed) with the same force and effect as if such facsimile or PDF signature were an original thereof.
- 9. Except to the extent that U.S. federal law preempts state law with respect to the matters covered hereby, this Assignment shall be governed by the law of the State of Delaware without reference to the choice of law doctrine of such state, and shall be subject to the provisions of Section 11.6 (Governing Law and Dispute Resolution) of the Asset Purchase Agreement.

[Remainder of Page Intentionally Left Blank]

IN WITNESS WHEREOF, Assignor, its Seller Affiliates, and Assignee have caused this Agreement to be executed by their respective duly authorized officers as of the date first above written.

ASSIGNOR

MEDTRONIC, INC.

Name: Chris Cleary
Title: Vice President

SELLER AFFILIATE

MEDTRONIC HOLDING COMPANY SÀRL

By: ______ Name: Title:

<u>SELLER AFFILIATE</u>

WARSAW ORTHOPEDIC, INC.

Name: Chris Cleary
Title: Vice President

IN WITNESS WHEREOF, Assignor, its Seller Affiliates, and Assignee have caused this Agreement to be executed by their respective duly authorized officers as of the date first above written.

MED	TRC)NIC,	INC.

By: _____

Name: Chris Cleary Title: Vice President

SELLER AFFILIATE

MEDTRONIC HOLDING COMPANY SÀRL

By: Marja Dallman
Name: Marja Dahlman

Title: Director

SELLER AFFILIATE

WARSAW ORTHOPEDIC, INC.

By: _____

Name: Chris Cleary
Title: Vice President

ASSIGNEE

COMPANION SPINE, LLC /

Name: Anthony G. Viscogliosi Title: Executive Chairman

[Signature Page to Assignment of Patents]

Schedule 1

Assigned Patents

A. DIAM / Injectable DIAM / Injectable Trial

Territory	Patent Number	Application Number	Filing Date
France	FR 2816197	0014367	11/7/2000
France	FR 2912896	0701335	2/26/2007
United States of America	US 8,118,839	12/513,100	5/19/2009
Europe (validated in Germany and France)	EP 2088949	07825612	11/7/2000
Japan	JP 5583804	2013047931	3/11/2013
United States of America	US 7,776,069	10/527,251	3/9/2005
Europe (validated in Germany and France)	EP 1545354	05745387	4/8/2005
United States of America	US 7,837,711	11/341,178	1/27/2006
United States of America	US 7,862,591	11/271,018	11/10/2005
United States of America	US 8,043,336	12/691,270	1/21/2010
United States of America	US 8,083,795	11/334,691	1/18/2006
United States of America	US 7,445,637	10/486,046	7/2/2004
Europe (validated in Germany and France)	EP 1414358	02749662	6/26/2002
France	FR 2828398	9201207	2/4/1992
Europe (validated in Germany and France)	EP 2004073	07734301	4/3/2007
Europe (validated in Germany and France)	EP 1981419	07701224	1/11/2007
United States of America	US 8,114,136	12/050,274	3/18/2008
United States of America	US 8,317,832	13/369,378	2/9/2012
Europe (validated in Germany and France)	EP 2278932	09722726	2/16/2009
United States of America	US 8,262,698	11/376,991	3/16/2006
United States of America	US 8,348,977	12/827,248	6/30/2010
United States of America	US 8,029,550	12/573,779	10/5/2009
United States of America	US 8,100,945	12/573,772	10/5/2009
United States of America	US 8,048,119	11/490,010	7/20/2006

B. Maverick

Territory	Patent Number	Application Number	Filing Date
United States of America	US 6,740,118 C1 (2010 Ex Parte Reexam Cert. # 7677)	10/042,589	1/9/2002
United States of America	US 7,331,995	10/773,814	2/6/2004
Europe (validated in Germany and France)	EP 1596774	04710692	2/12/2004
United States of America	US 7,364,589	10/752,860	1/7/2004
United States of America	US 7,503,934	10/774,157	2/6/2004
Europe (validated in Germany and France)	EP 1596775	04710704	2/12/2004
Australia	AU 2004220633	2004220633	2/12/2004
China	CN ZL200480007414.1	200480007414.1	2/12/2004
United States of America	US 7,850,735	10/774,135	2/6/2004
United States of America	US 8,591,553	12/943,656	11/10/2010
United States of America	US 8,617,243	12/942,774	11/9/2010
United States of America	US 7,547,308	10/768,354	1/30/2004

C. Bryan

Territory	Patent Number	Application Number	Filing Date
United States of America	US 6,562,045	09/934,507	8/22/2001
United States of America	US 6,949,105 ¹	09/923,891	8/7/2001
United States of America	US 7,025,787	10/303,569	11/25/2002
Europe (validated in Germany and France)	EP 1460978	02784591	11/26/2002
Japan	JP 4373790	2003563425	11/26/2002
Australia	AU 2002346524	2002346524	11/26/2002
United States of America	US 7,179,262	10/727,808	12/4/2003
United States of America	US 7,641,692	09/924,298	8/8/2001
United States of America	US 8,092,542	12/624,160	11/23/2009

D. TORKS

Territory	Patent Number	Application Number	Filing Date
United States of America	US 7,846,186	11/994,195	12/28/2007
Europe (validated in	EP 1895920	06755958	6/20/2006
Germany and France)			

¹ Status: Expired

E. <u>ELIESS</u>

arritary	Patent Publication Number	Application Number	Filing Date
Japan	JP 2010502339A ²	2009527218	9/5/2007

² Status Abandoned